BRCA1 promoter methylation and pathogenic genomic alterations in homologous recombination and repair (HRR) genes are mutually exclusive in cancer patients.1,3-5
Identify More Patients
Identify more patients for PARPi therapy with BRCA1 promoter methylation.²
PARPi, poly (ADP-ribose) polymerase inhibitor.
Promoter methylation biomarkers can expand patient reach or predict response.1,2
Home Guardant Infinity™ for HCPs Treatment Selection Monitoring and MRD Assessment Guardant Infinity™ for BioPharma